ArticleNature methods2021
MISpheroID: a knowledgebase and transparency tool for minimum information in spheroid identity.
Abstract read
In one paragraph
Article in Nature methods, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Converting lysosomes into photothermal organelles enables nanoparticle-free tumor ablation via intracellular vapor bubbles.Science advances · 2026Article
- Radiomics analysis of 3D spheroids captures irradiation-induced structural and textural changes.Scientific reports · 2026Article
- Spheroid cultures reveal cancer stem cell enrichment and distinct chemotherapeutic response in triple-negative breast cancer.BMC cancer · 2026Article
- From bench to bedside: advancing our understanding of radioresistance in rectal cancer.Cancer metastasis reviews · 2026Review
- PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer.Cancer research · 2026Article
- From Luminal to Triple Negative: 3D Spheroids Reveal Molecular and Phenotypic Differences Across Breast Cancer Subtypes.International journal of molecular sciences · 2026Article
- Balancing stromal-induced complexity in 3D ovarian cancer models through heterotypic co-culture with fibroblasts or architected micro-scaffolds.Journal of biological engineering · 2026Article
- AI-integrated microfluidics for drug screening: From single cell to organ-on-a-chip.Acta pharmaceutica Sinica. B · 2026Review
- Free-floating long-term vascularized mesenchymal organoids.iScience · 2026Article
- HCS-3DX, a next-generation AI-driven automated 3D-oid high-content screening system.Nature communications · 2025Article
- Sequential orthogonal assays for longitudinal and endpoint characterization of three-dimensional spheroids.Nature protocols · 2025Review
- MIRO2-mediated mitochondrial transfer from cancer cells induces cancer-associated fibroblast differentiation.Nature cancer · 2025Article
- C5aR1 Promotes Invasion, Metastasis, and Poor Prognosis in Cutaneous Squamous Cell Carcinoma.The American journal of pathology · 2025Article
- A 3D Self-Assembly Platform Integrating Decellularized Matrix Recapitulates In Vivo Tumor Phenotypes and Heterogeneity.Cancer research · 2025Article
- Differential unfolded protein response regulation in KRAS silencing sensitive and innately resistant colorectal cancer cells.Scientific reports · 2025Article
- Single-cell light-sheet fluorescence 3D images of tumour-stroma spheroid multicultures.Scientific data · 2025Article
- Influence of experimental variables on spheroid attributes.Scientific reports · 2025Article
- The Adaptation of MCF-7 Breast Cancer Spheroids to the Chemotherapeutic Doxorubicin: The Dynamic Role of Phase I Drug Metabolizing Enzymes.Metabolites · 2025Article
- The Spheroid Light Microscopy Image Atlas for morphometrical analysis of three-dimensional cell cultures.Scientific data · 2025Article
- Image segmentation of treated and untreated tumor spheroids by fully convolutional networks.GigaScience · 2025Article
Corrections and comments
- Commented on by
Authors and funding
51 authors.
Arne Peirsman *Laboratory of Experimental Cancer Research, Cancer Research Institute, Ghent, Belgium.ORCID http://orcid.org/0000-0002-6519-8367
Eva Blondeel *Laboratory of Experimental Cancer Research, Cancer Research Institute, Ghent, Belgium.ORCID http://orcid.org/0000-0002-2570-2207
Tasdiq AhmedWallace H Coulter Department of Biomedical Engineering and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology and Emory School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-3297-9746
Jasper AnckaertOncoRNALab, Cancer Research Institute, Ghent, Belgium.
Dominique AudenaertVIB Screening Core and Ghent University Expertise Centre for Bioassay Development and Screening (C-BIOS-VIB), Ghent University, Ghent, Belgium.
Tom BoterbergDepartment of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
Krisztina BuzasDepartment of Immunology, University of Szeged, Faculty of Medicine-Faculty of Science and Informatics, Szeged, Hungary.
Neil CarragherInstitute of Genetics and Cancer, Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0001-5541-9747
Gastone CastellaniDepartment of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Flávia Castroi3S - Institute for Research and Innovation in Health, University of Porto, Porto, Portugal.ORCID http://orcid.org/0000-0002-2273-2806
Virginie Dangles-MarieTranslational Research Department, Institut Curie, PSL Research University, and Faculty of Pharmacy, Paris, France.
John DawsonInstitute of Genetics and Cancer, Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, UK.
Pascal De TullioCenter for Interdisciplinary Research on Medicines (CIRM), Metabolomics Group, Université de Liège, Liège, Belgium.
Elly De VlieghereLaboratory of Experimental Cancer Research, Cancer Research Institute, Ghent, Belgium.ORCID http://orcid.org/0000-0003-0618-2258
Sándor DedeyneLaboratory of Experimental Cancer Research, Cancer Research Institute, Ghent, Belgium.ORCID http://orcid.org/0000-0002-0031-1306
Herman DepypereMenopause and Breast Clinic, Ghent University Hospital, Ghent, Belgium.
Akos DiosdiSynthetic and Systems Biology Unit, Hungarian Academy of Sciences, Biological Research Center (BRC), Szeged, Hungary.ORCID http://orcid.org/0000-0002-3118-5576
Ruslan I DmitrievTissue Engineering and Biomaterials Group, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0002-0347-8718
Helmut DolznigInstitute of Medical Genetics, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-6063-3585
Suzanne FischerLaboratory of Experimental Cancer Research, Cancer Research Institute, Ghent, Belgium.ORCID http://orcid.org/0000-0002-1714-556X
Christian GespachINSERM U938 Hospital Saint-Antoine Research Center CRSA, Team Céline Prunier, TGFbeta Signaling in Cellular Plasticity and Cancer, Sorbonne University, Paris, France.
Vera GoossensVIB Screening Core and Ghent University Expertise Centre for Bioassay Development and Screening (C-BIOS-VIB), Ghent University, Ghent, Belgium.
Jyrki HeinoDepartment of Life Technologies, University of Turku, Turku, Finland.
An HendrixLaboratory of Experimental Cancer Research, Cancer Research Institute, Ghent, Belgium.ORCID http://orcid.org/0000-0002-1883-8309
Peter HorvathSynthetic and Systems Biology Unit, Hungarian Academy of Sciences, Biological Research Center (BRC), Szeged, Hungary.
Leoni A Kunz-SchughartOncoRay - National Center for Radiation Research in Oncology, University Hospital Carl Gustav Carus Dresden, Carl Gustav Carus Faculty of Medicine at TU Dresden, and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.ORCID http://orcid.org/0000-0003-3912-6594
Sebastiaan MaesPlastic, Reconstructive and Aesthetic Surgery, Ghent University Hospital, Ghent, Belgium.
Christophe MangodtLaboratory of Experimental Cancer Research, Cancer Research Institute, Ghent, Belgium.ORCID http://orcid.org/0000-0002-5465-6019
Pieter MestdaghOncoRNALab, Cancer Research Institute, Ghent, Belgium.ORCID http://orcid.org/0000-0001-7821-9684
Soňa MichlíkováOncoRay - National Center for Radiation Research in Oncology, University Hospital Carl Gustav Carus Dresden, Carl Gustav Carus Faculty of Medicine at TU Dresden, and Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.ORCID http://orcid.org/0000-0002-1658-4632
Maria José Oliveirai3S - Institute for Research and Innovation in Health, University of Porto, Porto, Portugal.ORCID http://orcid.org/0000-0002-0724-0272
Francesco PampaloniPhysical Biology Group, Buchmann Institute for Molecular Life Sciences (BMLS), Goethe Universität Frankfurt am Main, Frankfurt am Main, Germany.
Filippo PiccininiIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.ORCID http://orcid.org/0000-0002-0371-7782
Cláudio PinheiroLaboratory of Experimental Cancer Research, Cancer Research Institute, Ghent, Belgium.
Jennifer RahnDepartments of Oncology and Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Stephen M RobbinsDepartments of Oncology and Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Elina SiljamäkiDepartment of Life Technologies, University of Turku, Turku, Finland.
Patrick SteigemannLead Discovery, Nuvisan ICB, Berlin, Germany.ORCID http://orcid.org/0000-0003-4748-3989
Gwen SysDepartment of Orthopedics and Traumatology, Ghent University Hospital, Ghent University, Ghent, Belgium.
Shuichi TakayamaWallace H Coulter Department of Biomedical Engineering and Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology and Emory School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-4385-9080
Anna TeseiIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.ORCID http://orcid.org/0000-0002-8351-5952
Joeri TulkensLaboratory of Experimental Cancer Research, Cancer Research Institute, Ghent, Belgium.
Michiel Van WaeyenbergePlastic, Reconstructive and Aesthetic Surgery, Ghent University Hospital, Ghent, Belgium.
Jo VandesompeleOncoRNALab, Cancer Research Institute, Ghent, Belgium.ORCID http://orcid.org/0000-0001-6274-0184
Glenn WagemansLaboratory of Experimental Cancer Research, Cancer Research Institute, Ghent, Belgium.
Claudia WeindorferInstitute of Medical Genetics, Medical University of Vienna, Vienna, Austria.
Nurten YigitOncoRNALab, Cancer Research Institute, Ghent, Belgium.ORCID http://orcid.org/0000-0003-1183-8688
Nina ZablowskyLead Discovery, Nuvisan ICB, Berlin, Germany.
Michele ZanoniIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
Phillip BlondeelPlastic, Reconstructive and Aesthetic Surgery, Ghent University Hospital, Ghent, Belgium.
Olivier De WeverLaboratory of Experimental Cancer Research, Cancer Research Institute, Ghent, Belgium. olivier.dewever@ugent.be.ORCID http://orcid.org/0000-0002-5453-760X
Funding
Systems Bioengineering of Cancer Cell MigrationR01CA196018 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LINDERMAN, JENNIFER JEAN, LUKER, GARY D · 2015 to 2019
$2.2M3D High Throughput Model to Predict Drug Efficacy in Fibrosis Progression vs ReversalR21AG061687 · NIA · GEORGIA INSTITUTE OF TECHNOLOGY · PI HECKER, LOUISE, TAKAYAMA, SHUICHI · 2019 to 2020
$445kCancer Research UK 28596Cancer Research UK A28596Cancer Research UK A29368NCI NIH HHS R01 CA196018NIA NIH HHS R21 AG061687
Abstract
Spheroids are three-dimensional cellular models with widespread basic and translational application across academia and industry. However, methodological transparency and guidelines for spheroid research have not yet been established. The MISpheroID Consortium developed a crowdsourcing knowledgebase that assembles the experimental parameters of 3,058 published spheroid-related experiments. Interrogation of this knowledgebase identified heterogeneity in the methodological setup of spheroids. Empirical evaluation and interlaboratory validation of selected variations in spheroid methodology revealed diverse impacts on spheroid metrics. To facilitate interpretation, stimulate transparency and increase awareness, the Consortium defines the MISpheroID string, a minimum set of experimental parameters required to report spheroid research. Thus, MISpheroID combines a valuable resource and a tool for three-dimensional cellular models to mine experimental parameters and to improve reproducibility.
Indexed as
Cell ProliferationKnowledge BasesSoftwareTumor MicroenvironmentBiomarkers, TumorCell Culture TechniquesGene Expression Regulation, NeoplasticHumansNeoplasmsReproducibility of ResultsRNA-SeqSpheroids, CellularTumor Cells, CulturedBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.